{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=47", "query": { "intervention": "Blinded (placebo)", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 2208, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:37:38.041Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04484818", "title": "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Carcinoma" ], "interventions": [ { "name": "Darolutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 27, "start_date": "2021-03-01", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 115, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 88 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484818" }, { "nct_id": "NCT02531633", "title": "Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo to match sirukumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo to match prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 161, "start_date": "2015-10-16", "completion_date": "2018-03-21", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 13, "location_summary": "Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531633" }, { "nct_id": "NCT04816643", "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection, COVID-19" ], "interventions": [ { "name": "Biological/Vaccine: BNT162b2 10mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 20mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 30mcg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Biological/Vaccine: BNT162b2 3mcg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "15 Years", "sex": "ALL", "summary": "6 Months to 15 Years" }, "enrollment_count": 11837, "start_date": "2021-03-24", "completion_date": "2023-12-08", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04816643" }, { "nct_id": "NCT03817125", "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Placebo for antibiotic", "type": "DRUG" }, { "name": "Vancomycin pretreatment", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Matching Placebo for SER-401", "type": "DRUG" }, { "name": "SER-401", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-01-28", "completion_date": "2022-03-04", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817125" }, { "nct_id": "NCT01433289", "title": "Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Polyphenon E", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2010-12", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2023-05-19", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433289" }, { "nct_id": "NCT02705352", "title": "5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ectropion", "Skin Neoplasms" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Normal saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 1, "start_date": "2016-08-25", "completion_date": "2019-01-25", "has_results": true, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02705352" }, { "nct_id": "NCT06563115", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance" ], "interventions": [ { "name": "(PEG)-BHD1028 Single Ascending Dose", "type": "DRUG" }, { "name": "(PEG)-BHD1028 Multiple Ascending Dose", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EncuraGen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 64, "start_date": "2022-04-18", "completion_date": "2024-06-23", "has_results": false, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06563115" }, { "nct_id": "NCT04819100", "title": "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2021-12-20", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 15, "location_summary": "Los Angeles, California • Stockton, California • Torrance, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04819100" }, { "nct_id": "NCT00057707", "title": "Effects of Modafinil on Brain Function in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Functional MRI", "type": "PROCEDURE" }, { "name": "Neuropsychological Testing", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 176, "start_date": "2003-03-26", "completion_date": "2017-06-16", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057707" }, { "nct_id": "NCT01057030", "title": "Multiple Dose Japanese Bridging Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "BMS-708163", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "20 Years to 45 Years · Male only" }, "enrollment_count": 22, "start_date": "2010-03", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2011-01-25", "last_synced_at": "2026-10-17T15:37:38.041Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057030" } ] }